

INTRODUCTION

In Paris region HCV prevalence is 44% among drug users, 15% of the population living with HVC found out their chronicle infection at an advanced stage. Gaia's Fibroscan team operates since 2011 and found between 7.8 and 9.5% of severe fibrosis among drug users visiting drop in centers and OST programs in Paris region.

Gaia's low threshold addiction centre receives each year around 800 patients, most of them very precarious PWUD.

CHARACTERISTICS

Sex ratio

Male	84%
Female	16%

Average age

39,2	
<=24 year old	3.4%
<=30 year old	15.1%

41% borned out of France of which

22% Eastern Europe

Homeless	33%
Precarious housing	31%

RESOURCES

Disable welfare	8.6
No resources	38%

HEALTH COVERAGE

Welfare	21.1%
Have never done HIV screening	22%
HIV positive	7.5%
HVC positive	46.6%
Psychiatric background	44%



CONCLUSION

Given the high rate of liver failure among PWuD which increases liver relative morbidity and mortality, Gaia's team developed a model of care to enhanced HVC treatment. This model necessary includes social aspects of illness. Taking inspiration of this model, Paris Health Regional Agency will implement a hepatitis care process in 2016 for migrants, inmates and PWuD.


FROM AWARENESS TO TREATMENT : A COMPREHENSIVE HCV MODEL OF CARE

Dr Elisabeth Avril¹, Johann Volant².

(1) Manageress (email : elisabeth.avril@gaia-paris.fr) et (2) coordinator.



HCV TREATMENT N=80



METHODS

The HCV care program includes an assessment of drug consumptions, offer of OST, psychiatric treatment if necessary, acupuncture against craving, harm reduction services : needle and syringue exchanges with sterile paraphernalia, crack pipes delivery,



capacity building sessions on hepatitis, liver, alcohol; assessment of liver fibrosis through transient elastography (Fibroscan®)



and biological analysis and development of a by pass consultation in a reference hospital for hepatitis C. As well, the program proposes social support (housing, health care insurance, vouchers...) and peer support



Practically, Gaia's GP prescribed PegInF/RBV directly, weekly consultation with nurse or GP (reassurance, monitoring for side effects). Since end 2014, the Direct Acting Antiviral (DAA) regimens needs spécialiste consultation at the hospital. However Gaia's GP are part of the treatment decision process.



During the treatment, Gaia's team works on client's capacity to develop better treatment adherence and bring re-infection risks to him/her knowledge as safer and better injecting practices. Managing adverse events is also part of the follow up.



RESULTS

Since 2012, among all the drug users visiting Gaia, 250 HCV rapid tests were done along with 118 dried blood spots. 79 had positive antibodies, and 58 RNA PCR positive. In the same period, recruiting other users from the NEP, already tested, 80 persons were HCV treated in the centre with good adherence, little treatment interruptions, no re infection among them.

